- Overview and management of cardiac adverse events associated with tyrosine kinase inhibitorsDaniel J Lenihan
Vanderbilt Heart and Vascular Institute, Nashville, Tennessee 37232 8802, USA
Oncologist 18:900-8. 2013..However, cardiovascular (CV) events, including hypertension, heart failure, left ventricular systolic dysfunction, and QT prolongation, have emerged as potential adverse events (AEs) with TKI therapy...
- Cardiac toxicity in cancer survivorsDaniel J Lenihan
Divison of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee, USA
Cancer 119:2131-42. 2013..Recognition of specific cancer therapy and the increased cardiovascular risk is an ongoing task that will remain of paramount importance for optimal outcomes among cancer survivors...
- Late cardiac effects of cancer treatmentDaniel J Lenihan
Division of Cardiovascular Medicine, Vanderbilt Heart and Vascular Institute, Nashville, TN 37232 8802, USA
J Clin Oncol 30:3657-64. 2012..Future research on late cardiac effects in cancer survivors needs to include advanced cardiac imaging techniques, novel cardiac biomarkers, and genetic determinants of response to cancer treatment...
- Pooled analysis of cardiac safety in patients with cancer treated with pertuzumabD Lenihan
Department of Cardiovascular Medicine, Vanderbilt University, Nashville, TN 37232, USA
Ann Oncol 23:791-800. 2012..As HER signaling pathways are not only involved in oncogenesis, but also in myocardial homeostasis, an analysis of cardiac safety data was undertaken in a large group of patients treated with pertuzumab...